| Field | Row 1 |
|---|---|
| adsh | 0001628280-25-025955 |
| cik | 1089907 |
| name | SWK HOLDINGS CORP |
| sic | 6159 |
| countryba | US |
| stprba | TX |
| cityba | DALLAS |
| zipba | 75225 |
| bas1 | 5956 SHERRY LANE |
| bas2 | SUITE 650 |
| baph | 2142177253 |
| countryma | US |
| stprma | TX |
| cityma | DALLAS |
| zipma | 75225 |
| mas1 | 5956 SHERRY LANE |
| mas2 | SUITE 650 |
| countryinc | US |
| stprinc | DE |
| ein | 770435679 |
| former | KANA SOFTWARE INC |
| changed | 20011114 |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250515 |
| accepted | 2025-05-15 16:22:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | swkh-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001628280-25-025955 | 20250331 | Assets | 297961000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20241231 | Accounts Receivable Net | 5788000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 111000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-025955 | 20240331 | Amortization Of Financing Costs | 248000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Assets | 7786000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Assets | 331264000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Assets Current | 20254000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Assets Current | 75938000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Cash And Cash Equivalents At Carrying Value | 5927000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 262000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Deferred Income Taxes And Tax Credits | 1265000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Earnings Per Share Diluted | 0.0400 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Equity Securities Fv Ni Cost | 580000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Finance Lease Right Of Use Asset Amortization | 91000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20231231 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 9731000.0000 | USD | 0 | us-gaap/2024 | Financing Receivable Recorded Investment By Class Of Financing Receivable= Term Loans; | ||
| 0001628280-25-025955 | 20240331 | Foreign Currency Transaction Gain Loss Unrealized | -783000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Gain Loss On Disposition Of Assets1 | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Income Tax Expense Benefit | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Income Tax Expense Benefit | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Income Tax Expense Benefit | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Increase Decrease In Deferred Revenue | 1500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Increase Decrease In Foreign Currency Forward Contract | -409000.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20240331 | Increase Decrease In Other Operating Assets | 283000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Interest Expense Operating | 1256000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20241231 | Long Term Line Of Credit | 6233000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Net Income Loss | 4539000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-025955 | 20240331 | Net Realized Gain On Exercise Of Warrants | 143000.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20250331 | Operating Income Loss | 8113000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Other Assets Current | 2141000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Other Assets Noncurrent | 2993000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Other Liabilities Noncurrent | 309000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Preferred Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Proceeds From Warrant Exercises Investing Activities | 0.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20250331 | Property Plant And Equipment Net | 28000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 279000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 279000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development Segment; | ||
| 0001628280-25-025955 | 20250331 | Share Based Compensation | 307000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Stockholders Equity | 4419431000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-025955 | 20240331 | Stock Issued During Period Shares New Issues | 48918.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20240331 | Stock Issued During Period Shares Restricted Stock Award Forfeited | 6446.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20240331 | Stock Repurchased During Period Shares | 58298.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 4245000.0000 | USD | 0 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20240331 | Other Income | 46000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Accounts Receivable Net | 4676000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Collateral On Foreign Currency Forward Contract | 2750000.0000 | USD | 0 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20241231 | Contract With Customer Liability Current | 1500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Contract With Customer Liability Current | 1500000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Pharmaceutical Development Segment; | ||
| 0001628280-25-025955 | 20250331 | Deferred Income Tax Assets Net | 22219000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Deferred Income Taxes And Tax Credits | 229000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Depreciation Depletion And Amortization | 19000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Fair Value Adjustment Of Warrants | 424000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Fair Value Of Warrants Received With Finance Receivables | 0.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20250331 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 6862000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument Performance Status= Performing Financing Receivable; | ||
| 0001628280-25-025955 | 20240331 | Foreign Currency Transaction Gain Loss Before Tax | 87000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Gain Loss On Disposition Of Assets1 | -82000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | General And Administrative Expense | 1896000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | General And Administrative Expense | 704000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 697000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Increase Decrease In Accounts And Other Receivables | 1200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Increase Decrease In Other Operating Assets | -980000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Interest Expense Operating | 2000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Interest Paid Net | 173000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Interest Paid Net | 775000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | -105000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Marketable Securities Unrealized Gain Loss | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Net Cash Provided By Used In Operating Activities | 4430000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Notes And Loans Receivable Net Noncurrent | 0.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; | ||
| 0001628280-25-025955 | 20250331 | Notes And Loans Receivable Net Noncurrent | 223076000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Payments To Acquire Finance Receivables | 10000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Payments To Acquire Property Plant And Equipment | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Proceeds From Repayments Of Lines Of Credit | -12350000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Proceeds From Sale Of Property Plant And Equipment | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Research And Development Expense | 758000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20231231 | Stockholders Equity | 4425104000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-025955 | 20240331 | Stockholders Equity | 4424216000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-025955 | 20250331 | Stockholders Equity | 292669000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Stockholders Equity | -4126774000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-025955 | 20231231 | Warrant Assets | 1759000.0000 | USD | 0 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 0.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; | ||
| 0001628280-25-025955 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 12240000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount | -3727000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Deferred Income Tax Assets Net | 23484000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Depreciation Depletion And Amortization | 492000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20231231 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 13901000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20231231 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 4170000.0000 | USD | 0 | us-gaap/2024 | Financing Receivable Recorded Investment By Class Of Financing Receivable= Royalty Purchases; | ||
| 0001628280-25-025955 | 20241231 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 11249000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 7158000.0000 | USD | 0 | us-gaap/2024 | Financing Receivable Recorded Investment By Class Of Financing Receivable= Term Loans; | ||
| 0001628280-25-025955 | 20250331 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 1923000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument Performance Status= Nonperforming Financing Receivable; | ||
| 0001628280-25-025955 | 20250331 | Gain Loss On Sale Of Notes Receivable | 1729000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | General And Administrative Expense | 78000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Income Tax Expense Benefit | 229000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Income Tax Expense Benefit | 1278000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Increase Decrease In Deferred Revenue | 1849000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Interest And Fee Income Loans And Leases | 11035000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Interest Expense Operating | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Liabilities | 38595000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Liabilities Current | 6719000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Liabilities Of Disposal Group Including Discontinued Operation Current | 1255000.0000 | USD | 0 | us-gaap/2024 | Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; | ||
| 0001628280-25-025955 | 20250331 | Liabilities Of Disposal Group Including Discontinued Operation Current | 1325000.0000 | USD | 0 | us-gaap/2024 | Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; | ||
| 0001628280-25-025955 | 20240331 | Net Income Loss | 4068000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20241231 | Notes And Loans Receivable Net Noncurrent | 277760000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Other Assets Noncurrent | 2553000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Other Income | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Other Income | 110000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Payments For Repurchase Of Common Stock | 867000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Preferred Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Proceeds From Repayments Of Accounts Receivable Securitization | 32684000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Proceeds From Sale Of Property Plant And Equipment | 110000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Revenues | 11360000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Unsecured Long Term Debt | 31567000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 4366000.0000 | USD | 0 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 0.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-025955 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 12475000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Accounts Payable And Accrued Liabilities Current | 2810000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 111000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Amortization Of Deferred Loan Origination Fees Net | 1487000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Assets | 9013000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5498000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5927000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001628280-25-025955 | 20250331 | Common Stock Shares Issued | 12222522.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20231231 | Common Stock Shares Outstanding | 12497770.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20241231 | Common Stock Shares Outstanding | 12213599.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Common Stock Shares Outstanding | 12222522.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Depreciation Depletion And Amortization | 22000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Earnings Per Share Basic | 0.3700 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Equity Securities Fv Ni Cost | 455000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Fair Value Of Warrants Received With Finance Receivables | 253000.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20241231 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 9174000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument Performance Status= Performing Financing Receivable; | ||
| 0001628280-25-025955 | 20250331 | Financing Receivable Transfer To Held For Sale Valuation Allowance Expense | 33990000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Foreign Currency Transaction Gain Loss Before Tax | 313000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Increase Decrease In Accounts Payable And Accrued Liabilities | -872000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Interest Expense Operating | 1130000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Liabilities And Stockholders Equity | 332235000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Liabilities And Stockholders Equity | 331264000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Net Cash Provided By Used In Investing Activities | 9181000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Net Cash Provided By Used In Investing Activities | 22702000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Net Cash Provided By Used In Operating Activities | 8280000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Net Income Loss | -4711000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Notes And Loans Receivable Net Noncurrent | 223076000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure; | ||
| 0001628280-25-025955 | 20240331 | Paid In Kind Interest Capitzlied | 478000.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Proceeds From Repayments Of Accounts Receivable Securitization | 9362000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Provision For Other Credit Losses | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Provision For Other Credit Losses | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Repayment Of Corporate Debt Securities | 8000.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20240331 | Research And Development Expense | 530000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Research And Development Expense | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Retained Earnings Accumulated Deficit | -4126774000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 279000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development Segment; Product Or Service= Pharmaceutical Development; | ||
| 0001628280-25-025955 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 963000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Stockholders Equity | 288690000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Stockholders Equity | 4419991000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-025955 | 20241231 | Stockholders Equity | -4131313000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-025955 | 20250331 | Stockholders Equity | 12000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20250331 | Stock Repurchased During Period Value | 867000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 0.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; | ||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 4366000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; | ||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 4245000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; | ||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 4245000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-025955 | 20250331 | Additional Paid In Capital | 4419431000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Assets Of Disposal Group Including Discontinued Operation Current | 6398000.0000 | USD | 0 | us-gaap/2024 | Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; | ||
| 0001628280-25-025955 | 20250331 | Assets Of Disposal Group Including Discontinued Operation Current | 6409000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 3920000.0000 | USD | 0 | us-gaap/2024 | Financing Receivable Recorded Investment By Class Of Financing Receivable= Royalty Purchases; | ||
| 0001628280-25-025955 | 20250331 | Foreign Currency Transaction Gain Loss Unrealized | 558000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | General And Administrative Expense | 710000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Income Tax Expense Benefit | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Increase Decrease In Accounts And Other Receivables | 1623000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Increase Decrease In Foreign Currency Forward Contract | 870000.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20240331 | Interest Expense Operating | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20241231 | Liabilities | 43545000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Long Term Line Of Credit | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Notes And Loans Receivable Net Noncurrent | 0.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; | ||
| 0001628280-25-025955 | 20241231 | Notes And Loans Receivable Net Noncurrent | 277760000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; | ||
| 0001628280-25-025955 | 20250331 | Notes And Loans Receivable Net Noncurrent | 223076000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Measurement Basis= Estimate Of Fair Value Fair Value Disclosure; | ||
| 0001628280-25-025955 | 20250331 | Other Assets Current | 1054000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Other Income | 46000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Other Income | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Proceeds From Repayments Of Lines Of Credit | -6233000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Property Plant And Equipment Net | 48000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Provision For Other Credit Losses | -1465000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Research And Development Expense | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Research And Development Expense | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20241231 | Retained Earnings Accumulated Deficit | -4131313000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20231231 | Stockholders Equity | 280315000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20231231 | Stockholders Equity | -4144801000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-025955 | 20240331 | Stockholders Equity | -4144333000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-025955 | 20250331 | Stock Issued During Period Shares New Issues | 61260.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20250331 | Trade And Loans Receivables Held For Sale Net Not Part Of Disposal Group | 33990000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Warrant Assets | 610000.0000 | USD | 0 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 0.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; | ||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 4366000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure; | ||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 0.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 0.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-025955 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 307000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Assets Of Disposal Group Including Discontinued Operation Current | 6398000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Cash And Cash Equivalents At Carrying Value | 29809000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5236000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Common Stock Shares Authorized | 250000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Common Stock Shares Issued | 12213599.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Common Stock Value | 12000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20231231 | Contract With Customer Liability Current | 9000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Pharmaceutical Development Segment; | ||
| 0001628280-25-025955 | 20240331 | Depreciation Depletion And Amortization | 514000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Depreciation Depletion And Amortization | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Depreciation Depletion And Amortization | 19000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20240331 | Fair Value Adjustment Of Warrants | 95000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 2075000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument Performance Status= Nonperforming Financing Receivable; | ||
| 0001628280-25-025955 | 20241231 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 4091000.0000 | USD | 0 | us-gaap/2024 | Financing Receivable Recorded Investment By Class Of Financing Receivable= Royalty Purchases; | ||
| 0001628280-25-025955 | 20250331 | General And Administrative Expense | 3277000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Interest Expense Operating | 232000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20241231 | Liabilities Current | 5565000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Marketable Securities Unrealized Gain Loss | -143000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Net Cash Provided By Used In Financing Activities | -13349000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Net Cash Provided By Used In Financing Activities | -7100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Net Income Loss | -1453000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Net Income Loss | 4539000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Notes And Loans Receivable Net Noncurrent | 277760000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure; | ||
| 0001628280-25-025955 | 20250331 | Notes And Loans Receivable Net Noncurrent | 0.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; | ||
| 0001628280-25-025955 | 20250331 | Other Income | 157000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Payments To Acquire Finance Receivables | 446000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Provision For Other Credit Losses | -1465000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Research And Development Expense | 530000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 963000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development Segment; | ||
| 0001628280-25-025955 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 963000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development Segment; Product Or Service= Pharmaceutical Development; | ||
| 0001628280-25-025955 | 20240331 | Share Based Compensation | 111000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Stockholders Equity | 279895000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Stock Repurchased During Period Shares | 52337.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20240331 | Unrealized Gain Loss On Derivatives | -95000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 4245000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure; | ||
| 0001628280-25-025955 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 12496000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Additional Paid In Capital | 4419991000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 307000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-025955 | 20241231 | Assets | 25201000.0000 | USD | 0 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 29809000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001628280-25-025955 | 20240331 | Common Stock Shares Outstanding | 12481944.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20241231 | Common Stock Shares Outstanding | 12213599.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20250331 | Contract With Customer Liability Current | 3349000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Pharmaceutical Development Segment; | ||
| 0001628280-25-025955 | 20240331 | Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Earnings Per Share Diluted | 0.3700 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 13198000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 1923000.0000 | USD | 0 | us-gaap/2024 | Financing Receivable Recorded Investment By Class Of Financing Receivable= Royalty Purchases; | ||
| 0001628280-25-025955 | 20240331 | General And Administrative Expense | 2684000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | General And Administrative Expense | 55000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | General And Administrative Expense | 2518000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20240331 | Income Tax Expense Benefit | 229000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Income Tax Expense Benefit | 1278000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20240331 | Increase Decrease In Accounts Payable And Accrued Liabilities | -1189000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Interest And Fee Income Loans And Leases | 10712000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Interest Expense Operating | 896000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Liabilities Of Disposal Group Including Discontinued Operation Current | 1325000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Net Income Loss | 468000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Net Income Loss | -536000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20241231 | Notes And Loans Receivable Net Noncurrent | 277760000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Measurement Basis= Estimate Of Fair Value Fair Value Disclosure; | ||
| 0001628280-25-025955 | 20250331 | Notes And Loans Receivable Net Noncurrent | 0.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; | ||
| 0001628280-25-025955 | 20250331 | Notes And Loans Receivable Net Noncurrent | 223076000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; | ||
| 0001628280-25-025955 | 20250331 | Other Income | 47000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Other Income | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20240331 | Payments For Repurchase Of Common Stock | 999000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Provision For Other Credit Losses | 5297000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Research And Development Expense | 758000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20241231 | Trade And Loans Receivables Held For Sale Net Not Part Of Disposal Group | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Unrealized Gain Loss On Derivatives | -424000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Unsecured Long Term Debt | 31412000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 0.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 4366000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 4366000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 0.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; | ||
| 0001628280-25-025955 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 12229000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Collateral On Foreign Currency Forward Contract | 2750000.0000 | USD | 0 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20241231 | Common Stock Shares Authorized | 250000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Common Stock Value | 12000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Contract With Customer Liability Current | 3349000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Accounts Payable And Accrued Liabilities Current | 2045000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Amortization Of Deferred Loan Origination Fees Net | 837000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Amortization Of Financing Costs | 262000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Assets | 332235000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Assets | 299248000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Assets | 24290000.0000 | USD | 0 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Assets Of Disposal Group Including Discontinued Operation Current | 6409000.0000 | USD | 0 | us-gaap/2024 | Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; | ||
| 0001628280-25-025955 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 23882000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Common Stock Shares Outstanding | 12222522.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20240331 | Depreciation Depletion And Amortization | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Depreciation Depletion And Amortization | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Earnings Per Share Basic | 0.0400 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Finance Lease Right Of Use Asset Amortization | 80000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 9278000.0000 | USD | 0 | us-gaap/2024 | Financing Receivable Recorded Investment By Class Of Financing Receivable= Term Loans; | ||
| 0001628280-25-025955 | 20250331 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 8785000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | 6862000.0000 | USD | 0 | us-gaap/2024 | Financing Receivable Recorded Investment By Class Of Financing Receivable= Term Loans; | ||
| 0001628280-25-025955 | 20240331 | Financing Receivable Transfer To Held For Sale Valuation Allowance Expense | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Gain Loss On Sale Of Notes Receivable | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 5817000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Interest Expense Operating | 1256000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Liabilities Of Disposal Group Including Discontinued Operation Current | 1255000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | -231000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Net Income Loss | -2147000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20240331 | Net Income Loss | 468000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-025955 | 20250331 | Net Income Loss | 9786000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Net Realized Gain On Exercise Of Warrants | 0.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20240331 | Operating Income Loss | 1079000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Other Liabilities Noncurrent | 335000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20250331 | Paid In Kind Interest Capitzlied | 186000.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20250331 | Payments To Acquire Property Plant And Equipment | 100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Proceeds From Warrant Exercises Investing Activities | 258000.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20240331 | Provision For Other Credit Losses | 5297000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Provision For Other Credit Losses | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-025955 | 20250331 | Provision For Other Credit Losses | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pharmaceutical Development And Other Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20240331 | Repayment Of Corporate Debt Securities | 7000.0000 | USD | 1 | 0001628280-25-025955 | |||
| 0001628280-25-025955 | 20240331 | Research And Development Expense | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Finance Receivables Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-025955 | 20250331 | Revenues | 11832000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20231231 | Stockholders Equity | 12000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20240331 | Stockholders Equity | 12000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20241231 | Stockholders Equity | 12000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-025955 | 20240331 | Stock Repurchased During Period Value | 999000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-025955 | 20240331 | Stock Repurchased During Period Value | 999000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-025955 | 20250331 | Stock Repurchased During Period Value | 867000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-025955 | 20241231 | Warrant Assets | 4366000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Measurement Basis= Estimate Of Fair Value Fair Value Disclosure; | ||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 4245000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-025955 | 20250331 | Warrant Assets | 4245000.0000 | USD | 0 | 0001628280-25-025955 | Fair Value By Measurement Basis= Estimate Of Fair Value Fair Value Disclosure; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Deferred Income Tax Assets Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Deferred Income Tax Assets, Net | Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. |
| Marketable Securities Unrealized Gain Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Marketable Security, Unrealized Gain (Loss) | Amount of unrealized gain (loss) on investment in marketable security. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Accounts Payable And Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable and Accrued Liabilities, Current | Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Liabilities Of Disposal Group Including Discontinued Operation Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Disposal Group, Including Discontinued Operation, Liabilities, Current | Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. |
| Other Income | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Income | Amount of revenue and income classified as other. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Trade And Loans Receivables Held For Sale Net Not Part Of Disposal Group | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts and Financing Receivables, Held-for-Sale, Not Part of Disposal Group, after Valuation Allowance | Amount, after valuation allowance, of accounts and financing receivables held for sale and not part of disposal group. Excludes loan covered under loss sharing agreement and loan classified as investment in debt security. |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Gain Loss On Disposition Of Assets1 | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss) on Disposition of Assets | Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Provision For Other Credit Losses | us-gaap/2024 | 0 | 0 | monetary | D | D | Provision for Other Credit Losses | Amount of expense related to credit loss from transactions other than loan and lease transactions. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Increase Decrease In Foreign Currency Forward Contract | 0001628280-25-025955 | 1 | 0 | monetary | D | C | Increase (Decrease) in Foreign Currency Forward Contract | Increase (Decrease) in Foreign Currency Forward Contract |
| Accounts Receivable Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Equity Securities Fv Ni Cost | us-gaap/2024 | 0 | 0 | monetary | I | D | Equity Securities, FV-NI, Cost | Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value. |
| Foreign Currency Transaction Gain Loss Unrealized | us-gaap/2024 | 0 | 0 | monetary | D | C | Unrealized Gain (Loss), Foreign Currency Transaction, before Tax | Amount, before tax, of unrealized gain (loss) from foreign currency transaction. |
| Increase Decrease In Accounts And Other Receivables | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts and Other Receivables | The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. |
| Interest And Fee Income Loans And Leases | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest and Fee Income, Loans and Leases | The aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases. |
| Interest Expense Operating | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Operating | Amount of interest expense classified as operating. |
| Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | us-gaap/2024 | 0 | 0 | monetary | D | C | Marketable Security, Realized Gain (Loss) | Amount of realized gain (loss) on investment in marketable security. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Paid In Kind Interest Capitzlied | 0001628280-25-025955 | 1 | 0 | monetary | D | C | Paid-in-Kind Interest, Capitzlied | Paid-in-Kind Interest, Capitzlied |
| Financing Receivable Transfer To Held For Sale Valuation Allowance Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Financing Receivable, Transfer to Held-for-Sale, Valuation Allowance, Expense | Amount of expense for valuation allowance on financing receivable transferred to held-for-sale classification. |
| Increase Decrease In Other Operating Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Operating Assets | Amount of increase (decrease) in operating assets classified as other. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Proceeds From Repayments Of Lines Of Credit | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from (Repayments of) Lines of Credit | The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets). |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Collateral On Foreign Currency Forward Contract | 0001628280-25-025955 | 1 | 0 | monetary | I | D | Collateral On Foreign Currency Forward Contract | Collateral On Foreign Currency Forward Contract |
| Fair Value Of Warrants Received With Finance Receivables | 0001628280-25-025955 | 1 | 0 | monetary | D | D | Fair Value Of Warrants Received With Finance Receivables | Fair Value Of Warrants Received With Finance Receivables |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Finance Lease Right Of Use Asset Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Finance Lease, Right-of-Use Asset, Amortization | Amount of amortization expense attributable to right-of-use asset from finance lease. |
| Foreign Currency Transaction Gain Loss Before Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss), Foreign Currency Transaction, before Tax | Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. |
| Long Term Line Of Credit | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Line of Credit, Noncurrent | The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Proceeds From Sale Of Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale of Property, Plant, and Equipment | The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. |
| Stock Issued During Period Shares Restricted Stock Award Forfeited | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Restricted Stock Award, Forfeited | Number of shares related to Restricted Stock Award forfeited during the period. | |
| Stock Repurchased During Period Value | us-gaap/2024 | 0 | 0 | monetary | D | D | Stock Repurchased During Period, Value | Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. |
| Warrant Assets | 0001628280-25-025955 | 1 | 0 | monetary | I | D | Warrant Assets | Warrant Assets |
| Amortization Of Deferred Loan Origination Fees Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Amortization of Deferred Loan Origination Fees, Net | The net increase(decrease) in interest income during the period representing the allocation of deferred loan origination fees less deferred loan origination costs using the effective interest method over the term of the debt arrangement to which they pertain taking into account the effect of prepayments. |
| Assets Of Disposal Group Including Discontinued Operation Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Disposal Group, Including Discontinued Operation, Assets, Current | Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. |
| Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount | us-gaap/2024 | 0 | 0 | monetary | D | C | Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount | Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Current | Amount of current assets classified as other. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Payments To Acquire Finance Receivables | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Finance Receivables | The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. |
| Stock Repurchased During Period Shares | us-gaap/2024 | 0 | 0 | shares | D | Stock Repurchased During Period, Shares | Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. | |
| Amortization Of Financing Costs | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Debt Issuance Costs | Amount of amortization expense attributable to debt issuance costs. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Gain Loss On Sale Of Notes Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss) on Sale of Financing Receivable | Amount of gain (loss) on sale of financing receivable. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Notes And Loans Receivable Net Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Financing Receivable, after Allowance for Credit Loss, Noncurrent | Amount, after allowance for credit loss, of financing receivable, classified as noncurrent. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Revenues | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
| Stock Issued During Period Shares New Issues | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| Unrealized Gain Loss On Derivatives | us-gaap/2024 | 0 | 0 | monetary | D | C | Unrealized Gain (Loss) on Derivatives | The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Repayment Of Corporate Debt Securities | 0001628280-25-025955 | 1 | 0 | monetary | D | D | Repayment Of Corporate Debt Securities | Repayment Of Corporate Debt Securities |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Fair Value Adjustment Of Warrants | us-gaap/2024 | 0 | 0 | monetary | D | D | Fair Value Adjustment of Warrants | Amount of expense (income) related to adjustment to fair value of warrant liability. |
| Interest Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activities | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Payments For Repurchase Of Common Stock | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments for Repurchase of Common Stock | The cash outflow to reacquire common stock during the period. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Proceeds From Repayments Of Accounts Receivable Securitization | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from (Repayments of) Accounts Receivable Securitization | Proceeds from (repayments of) securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Contract With Customer Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Contract with Customer, Liability, Current | Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. |
| Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest | Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease. |
| Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Increase Decrease In Deferred Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Deferred Revenue | Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. |
| Deferred Income Taxes And Tax Credits | us-gaap/2024 | 0 | 0 | monetary | D | D | Deferred Income Taxes and Tax Credits | Amount of deferred income tax expense (benefit) and income tax credits. |
| Net Realized Gain On Exercise Of Warrants | 0001628280-25-025955 | 1 | 0 | monetary | D | D | Net Realized Gain On Exercise Of Warrants | Net Realized Gain On Exercise Of Warrants |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Unsecured Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | I | C | Unsecured Long-Term Debt, Noncurrent | Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Proceeds From Warrant Exercises Investing Activities | 0001628280-25-025955 | 1 | 0 | monetary | D | D | Proceeds from Warrant Exercises, Investing Activities | Proceeds from Warrant Exercises, Investing Activities |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001628280-25-025955 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001628280-25-025955 | 2 | 4 | BS | 0 | H | Accounts Receivable Net | us-gaap/2024 | Interest, accounts receivable and other receivables, net | 0 |
| 0001628280-25-025955 | 2 | 5 | BS | 0 | H | Assets Of Disposal Group Including Discontinued Operation Current | us-gaap/2024 | Assets held for sale, net (Note 4) | 0 |
| 0001628280-25-025955 | 2 | 6 | BS | 0 | H | Trade And Loans Receivables Held For Sale Net Not Part Of Disposal Group | us-gaap/2024 | Finance receivables and related interest receivable held for sale (Note 4) | 0 |
| 0001628280-25-025955 | 2 | 7 | BS | 0 | H | Other Assets Current | us-gaap/2024 | Other current assets | 0 |
| 0001628280-25-025955 | 2 | 8 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001628280-25-025955 | 2 | 9 | BS | 0 | H | Notes And Loans Receivable Net Noncurrent | us-gaap/2024 | Finance receivables, net of allowance for credit losses of $8,785 and $11,249 as of March 31, 2025 and December 31, 2024, respectively | 0 |
| 0001628280-25-025955 | 2 | 10 | BS | 0 | H | Collateral On Foreign Currency Forward Contract | 0001628280-25-025955 | Collateral on foreign currency forward contract | 0 |
| 0001628280-25-025955 | 2 | 11 | BS | 0 | H | Equity Securities Fv Ni Cost | us-gaap/2024 | Marketable investments | 0 |
| 0001628280-25-025955 | 2 | 12 | BS | 0 | H | Deferred Income Tax Assets Net | us-gaap/2024 | Deferred tax assets, net | 0 |
| 0001628280-25-025955 | 2 | 13 | BS | 0 | H | Warrant Assets | 0001628280-25-025955 | Warrant assets | 0 |
| 0001628280-25-025955 | 2 | 14 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0001628280-25-025955 | 2 | 15 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other non-current assets | 0 |
| 0001628280-25-025955 | 2 | 16 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001628280-25-025955 | 2 | 19 | BS | 0 | H | Accounts Payable And Accrued Liabilities Current | us-gaap/2024 | Accounts payable and accrued liabilities | 0 |
| 0001628280-25-025955 | 2 | 20 | BS | 0 | H | Liabilities Of Disposal Group Including Discontinued Operation Current | us-gaap/2024 | Liabilities held for sale (Note 4) | 0 |
| 0001628280-25-025955 | 2 | 21 | BS | 0 | H | Contract With Customer Liability Current | us-gaap/2024 | Deferred income | 0 |
| 0001628280-25-025955 | 2 | 22 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001628280-25-025955 | 2 | 23 | BS | 0 | H | Unsecured Long Term Debt | us-gaap/2024 | Unsecured senior notes, net | 0 |
| 0001628280-25-025955 | 2 | 24 | BS | 0 | H | Long Term Line Of Credit | us-gaap/2024 | Revolving credit facility | 0 |
| 0001628280-25-025955 | 2 | 25 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other non-current liabilities | 0 |
| 0001628280-25-025955 | 2 | 26 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001628280-25-025955 | 2 | 27 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 7) | 0 |
| 0001628280-25-025955 | 2 | 29 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding | 0 |
| 0001628280-25-025955 | 2 | 30 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, $0.001 par value; 250,000,000 shares authorized; 12,222,522 and 12,213,599 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 0 |
| 0001628280-25-025955 | 2 | 31 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001628280-25-025955 | 2 | 32 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001628280-25-025955 | 2 | 33 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders' equity | 0 |
| 0001628280-25-025955 | 2 | 34 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity | 0 |
| 0001628280-25-025955 | 6 | 13 | CF | 0 | H | Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | us-gaap/2024 | Loss on marketable investments | 1 |
| 0001628280-25-025955 | 3 | 1 | BS | 1 | H | Financing Receivable Allowance For Credit Loss Excluding Accrued Interest | us-gaap/2024 | Financing receivable, allowance for credit loss excluding accrued interest | 0 |
| 0001628280-25-025955 | 3 | 2 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par or stated value per share (in dollars per share) | 0 |
| 0001628280-25-025955 | 3 | 3 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized (in shares) | 0 |
| 0001628280-25-025955 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued (in shares) | 0 |
| 0001628280-25-025955 | 3 | 5 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding (in shares) | 0 |
| 0001628280-25-025955 | 3 | 6 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par or stated value per share (in dollars per share) | 0 |
| 0001628280-25-025955 | 3 | 7 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized (in shares) | 0 |
| 0001628280-25-025955 | 3 | 8 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares, issued (in shares) | 0 |
| 0001628280-25-025955 | 3 | 9 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares, outstanding (in shares) | 0 |
| 0001628280-25-025955 | 4 | 2 | IS | 0 | H | Interest And Fee Income Loans And Leases | us-gaap/2024 | Finance receivable interest income, including fees | 0 |
| 0001628280-25-025955 | 4 | 3 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Pharmaceutical development | 0 |
| 0001628280-25-025955 | 4 | 4 | IS | 0 | H | Other Income | us-gaap/2024 | Other | 0 |
| 0001628280-25-025955 | 4 | 5 | IS | 0 | H | Revenues | us-gaap/2024 | Total revenues | 0 |
| 0001628280-25-025955 | 4 | 7 | IS | 0 | H | Provision For Other Credit Losses | us-gaap/2024 | Provision (benefit) for credit losses | 0 |
| 0001628280-25-025955 | 4 | 8 | IS | 0 | H | Interest Expense Operating | us-gaap/2024 | Interest expense | 0 |
| 0001628280-25-025955 | 4 | 9 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Pharmaceutical manufacturing, research and development expense | 0 |
| 0001628280-25-025955 | 4 | 10 | IS | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation and amortization expense | 0 |
| 0001628280-25-025955 | 4 | 11 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative expense | 0 |
| 0001628280-25-025955 | 4 | 12 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Income from operations | 0 |
| 0001628280-25-025955 | 4 | 14 | IS | 0 | H | Unrealized Gain Loss On Derivatives | us-gaap/2024 | Unrealized net loss on warrants | 0 |
| 0001628280-25-025955 | 4 | 15 | IS | 0 | H | Marketable Securities Unrealized Gain Loss | us-gaap/2024 | Net loss on exercise and cancellation of warrants | 0 |
| 0001628280-25-025955 | 4 | 16 | IS | 0 | H | Gain Loss On Disposition Of Assets1 | us-gaap/2024 | Loss on sale of assets | 0 |
| 0001628280-25-025955 | 4 | 17 | IS | 0 | H | Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | us-gaap/2024 | Net loss on marketable investments | 0 |
| 0001628280-25-025955 | 4 | 18 | IS | 0 | H | Gain Loss On Sale Of Notes Receivable | us-gaap/2024 | Realized gain on early payment of finance receivable | 0 |
| 0001628280-25-025955 | 4 | 19 | IS | 0 | H | Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount | us-gaap/2024 | Loss on revaluation of finance receivables held for sale | 0 |
| 0001628280-25-025955 | 4 | 20 | IS | 0 | H | Foreign Currency Transaction Gain Loss Before Tax | us-gaap/2024 | Realized and unrealized foreign currency transaction gains | 0 |
| 0001628280-25-025955 | 4 | 21 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Income before income tax expense | 0 |
| 0001628280-25-025955 | 4 | 22 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax expense | 0 |
| 0001628280-25-025955 | 4 | 23 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net income | 0 |
| 0001628280-25-025955 | 4 | 25 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Basic (in dollars per share) | 0 |
| 0001628280-25-025955 | 4 | 26 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Diluted (in dollars per share) | 0 |
| 0001628280-25-025955 | 4 | 28 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Basic (in shares) | 0 |
| 0001628280-25-025955 | 4 | 29 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Diluted (in shares) | 0 |
| 0001628280-25-025955 | 5 | 9 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Beginning balance (in shares) | 0 |
| 0001628280-25-025955 | 5 | 10 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Beginning balance | 0 |
| 0001628280-25-025955 | 5 | 11 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation | 0 |
| 0001628280-25-025955 | 5 | 12 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2024 | Issuance of restricted common stock (in shares) | 0 |
| 0001628280-25-025955 | 5 | 13 | EQ | 0 | H | Stock Issued During Period Shares Restricted Stock Award Forfeited | us-gaap/2024 | Forfeiture of unvested restricted stock (in shares) | 1 |
| 0001628280-25-025955 | 5 | 14 | EQ | 0 | H | Stock Repurchased During Period Shares | us-gaap/2024 | Repurchases of common stock in open market (in shares) | 1 |
| 0001628280-25-025955 | 5 | 15 | EQ | 0 | H | Stock Repurchased During Period Value | us-gaap/2024 | Repurchases of common stock in open market | 1 |
| 0001628280-25-025955 | 5 | 16 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net income | 0 |
| 0001628280-25-025955 | 5 | 17 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Ending balance (in shares) | 0 |
| 0001628280-25-025955 | 5 | 18 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Ending balance | 0 |
| 0001628280-25-025955 | 6 | 2 | CF | 0 | H | Net Income Loss | us-gaap/2024 | Net income | 0 |
| 0001628280-25-025955 | 6 | 4 | CF | 0 | H | Provision For Other Credit Losses | us-gaap/2024 | Provision (benefit) for credit losses | 0 |
| 0001628280-25-025955 | 6 | 5 | CF | 0 | H | Finance Lease Right Of Use Asset Amortization | us-gaap/2024 | Right-of-use amortization and cease use costs | 0 |
| 0001628280-25-025955 | 6 | 6 | CF | 0 | H | Amortization Of Financing Costs | us-gaap/2024 | Amortization of debt issuance costs | 0 |
| 0001628280-25-025955 | 6 | 7 | CF | 0 | H | Deferred Income Taxes And Tax Credits | us-gaap/2024 | Deferred income taxes, net | 0 |
| 0001628280-25-025955 | 6 | 8 | CF | 0 | H | Fair Value Adjustment Of Warrants | us-gaap/2024 | Unrealized net loss on warrants | 0 |
| 0001628280-25-025955 | 6 | 9 | CF | 0 | H | Net Realized Gain On Exercise Of Warrants | 0001628280-25-025955 | Net loss from exercise and cancellation of warrants | 0 |
| 0001628280-25-025955 | 6 | 10 | CF | 0 | H | Gain Loss On Disposition Of Assets1 | us-gaap/2024 | Loss from sale of assets | 1 |
| 0001628280-25-025955 | 6 | 11 | CF | 0 | H | Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount | us-gaap/2024 | Loss on revaluation of finance receivables held for sale | 1 |
| 0001628280-25-025955 | 6 | 12 | CF | 0 | H | Foreign Currency Transaction Gain Loss Unrealized | us-gaap/2024 | Foreign currency transaction (gain) loss | 1 |
| 0001628280-25-025955 | 6 | 14 | CF | 0 | H | Amortization Of Deferred Loan Origination Fees Net | us-gaap/2024 | Loan discount amortization and fee accretion | 1 |
| 0001628280-25-025955 | 6 | 15 | CF | 0 | H | Paid In Kind Interest Capitzlied | 0001628280-25-025955 | Interest paid-in-kind | 1 |
| 0001628280-25-025955 | 6 | 16 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation | 0 |
| 0001628280-25-025955 | 6 | 17 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation and amortization expense | 0 |
| 0001628280-25-025955 | 6 | 19 | CF | 0 | H | Increase Decrease In Accounts And Other Receivables | us-gaap/2024 | Interest, accounts receivable and other receivables | 1 |
| 0001628280-25-025955 | 6 | 20 | CF | 0 | H | Increase Decrease In Foreign Currency Forward Contract | 0001628280-25-025955 | Foreign currency forward contract | 1 |
| 0001628280-25-025955 | 6 | 21 | CF | 0 | H | Increase Decrease In Other Operating Assets | us-gaap/2024 | Other assets | 1 |
| 0001628280-25-025955 | 6 | 22 | CF | 0 | H | Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | Accounts payable, accrued expenses, and other non-current liabilities | 0 |
| 0001628280-25-025955 | 6 | 23 | CF | 0 | H | Increase Decrease In Deferred Revenue | us-gaap/2024 | Deferred income | 0 |
| 0001628280-25-025955 | 6 | 24 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash provided by operating activities | 0 |
| 0001628280-25-025955 | 6 | 26 | CF | 0 | H | Proceeds From Sale Of Property Plant And Equipment | us-gaap/2024 | Proceeds from sale of property and equipment | 0 |
| 0001628280-25-025955 | 6 | 27 | CF | 0 | H | Proceeds From Warrant Exercises Investing Activities | 0001628280-25-025955 | Sale of marketable investments | 0 |
| 0001628280-25-025955 | 6 | 28 | CF | 0 | H | Payments To Acquire Finance Receivables | us-gaap/2024 | Investment in finance receivables | 1 |
| 0001628280-25-025955 | 6 | 29 | CF | 0 | H | Proceeds From Repayments Of Accounts Receivable Securitization | us-gaap/2024 | Repayment of finance receivables | 0 |
| 0001628280-25-025955 | 6 | 30 | CF | 0 | H | Repayment Of Corporate Debt Securities | 0001628280-25-025955 | Corporate debt securities principal payments | 0 |
| 0001628280-25-025955 | 6 | 31 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchases of property and equipment | 1 |
| 0001628280-25-025955 | 6 | 32 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash provided by investing activities | 0 |
| 0001628280-25-025955 | 6 | 34 | CF | 0 | H | Proceeds From Repayments Of Lines Of Credit | us-gaap/2024 | Net payments on credit facility | 0 |
| 0001628280-25-025955 | 6 | 35 | CF | 0 | H | Payments For Repurchase Of Common Stock | us-gaap/2024 | Repurchases of common stock, including fees and expenses | 1 |
| 0001628280-25-025955 | 6 | 36 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash used in financing activities | 0 |
| 0001628280-25-025955 | 6 | 37 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net increase in cash and cash equivalents | 0 |
| 0001628280-25-025955 | 6 | 38 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents at beginning of period | 0 |
| 0001628280-25-025955 | 6 | 39 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents at end of period | 0 |
| 0001628280-25-025955 | 6 | 41 | CF | 0 | H | Financing Receivable Transfer To Held For Sale Valuation Allowance Expense | us-gaap/2024 | Transfer of finance receivables and related interest receivable to held for sale | 0 |
| 0001628280-25-025955 | 6 | 42 | CF | 0 | H | Interest Paid Net | us-gaap/2024 | Cash paid for interest | 0 |
| 0001628280-25-025955 | 6 | 43 | CF | 0 | H | Fair Value Of Warrants Received With Finance Receivables | 0001628280-25-025955 | Fair value of warrants received with investment in finance receivables | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |